Translating Therapies for Huntington’s Disease from Genetic Animal Models to Clinical Trials

Por Hersch, Steven M., Ferrante, Robert J.
Publicado em 2004

Drug Targeting of Dysregulated Transcription in Huntington’s Disease

Por Kazantsev, Aleksey G., Hersch, Steven M.
Publicado em 2007

Neuroprotection for Huntington’s disease: Ready, set, slow

Por Hersch, Steven M., Rosas, H. Diana
Publicado em 2008

Using Advances in Neuroimaging to Detect, Understand, and Monitor Disease Progression in Huntington’s Disease

Por Rosas, H.D., Feigin, A.S., Hersch, Steven M.
Publicado em 2004

Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease

Por Stephen, Christopher D., Hung, Judy, Schifitto, Giovanni, Hersch, Steven M., Rosas, H. Diana
Publicado no Mov Disord Clin Pract (2018)

COMPLEXITY AND HETEROGENEITY: WHAT DRIVES THE EVER-CHANGING BRAIN IN HUNTINGTONS DISEASE?

Por Rosas, H. Diana, Salat, David H, Lee, Stephanie Y, Zaleta, Alexandra K, Hevelone, Nathanael, Hersch, Steven M.
Publicado em 2008

A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease

Por Rosas, Herminia D, Doros, Gheorghe, Bhasin, Swati, Thomas, Beena, Gevorkian, Sona, Malarick, Keith, Matson, Wayne, Hersch, Steven M
Publicado no Ann Clin Transl Neurol (2015)

The CREST-E study of creatine for Huntington disease: A randomized controlled trial

Por Hersch, Steven M., Schifitto, Giovanni, Oakes, David, Bredlau, Amy-Lee, Meyers, Catherine M., Nahin, Richard, Rosas, Herminia Diana
Publicado no Neurology (2017)

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington’s disease transgenic mice

Por Dedeoglu, Alpaslan, Kubilus, James K., Yang, Lichuan, Ferrante, Kimberly L., Hersch, Steven M., Beal, M. Flint, Ferrante, Robert J.
Publicado em 2003

A Tale of Two Factors: What determines rate of progression in Huntington Disease? A Longitudinal MRI study

Por Rosas, H. Diana, Reuter, Martin, Doros, Gheorghe, Lee, Stephanie Y., Triggs, Tyler, Malarick, Keith, Fischl, Bruce, Salat, David H., Hersch, Steven M.
Publicado em 2011

Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity

Por Rosas, H. Diana, Salat, David H., Lee, Stephanie Y., Zaleta, Alexandra K., Pappu, Vasanth, Fischl, Bruce, Greve, Doug, Hevelone, Nathanael, Hersch, Steven M.
Publicado em 2008

The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS

Por Maxwell, Michele M., Tomkinson, Elizabeth M., Nobles, Johnathan, Wizeman, John W., Amore, Allison M., Quinti, Luisa, Chopra, Vanita, Hersch, Steven M., Kazantsev, Aleksey G.
Publicado em 2011

Alterations in Brain Transition Metals in Huntington Disease: An Evolving and Intricate Story

Por Rosas, H. Diana, Chen, Y. Iris, Doros, Gheorghe, Salat, David H., Chen, Nan-kuei, Kwong, Ken K., Bush, Ashley, Fox, Jonathan, Hersch, Steven M.
Publicado em 2012

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of...

Por Frentzel Stefan, Hoyer Daniel, Betschart Claudia, Bleckmann Dorothee, Kama Jibrin A, Dorsey Kate, Chopra Vanita, Connor Teal, Fox Jonathan H, DiFiglia Marian, Paganetti Paolo, Hersch Steven M
Publicado em 2010-06-01

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of...

Por Fox, Jonathan H, Connor, Teal, Chopra, Vanita, Dorsey, Kate, Kama, Jibrin A, Bleckmann, Dorothee, Betschart, Claudia, Hoyer, Daniel, Frentzel, Stefan, DiFiglia, Marian, Paganetti, Paolo, Hersch, Steven M
Publicado em 2010

Altered White Matter Microstructure in the Corpus Callosum in Huntington’s Disease: implications for cortical “disconnection”

Por Diana Rosas, H, Lee, Stephanie Y, Bender, Alexander, Zaleta, Alexandra K, Vange, Mark, Yu, Peng, Fischl, Bruce, Pappu, Vasanth, Cha, Jang-Ho, Salat, David H, Hersch, Steven M.
Publicado em 2009

HTRF analysis of soluble huntingtin in PHAROS PBMCs

Por Moscovitch-Lopatin, Miriam, Goodman, Rachel E., Eberly, Shirley, Ritch, James J., Rosas, H. Diana, Matson, Samantha, Matson, Wayne, Oakes, David, Young, Anne B., Shoulson, Ira, Hersch, Steven M.
Publicado em 2013

PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Por Rosas, Herminia D., Doros, Gheorghe, Gevorkian, Sona, Malarick, Keith, Reuter, Martin, Coutu, Jean-Philippe, Triggs, Tyler D., Wilkens, Paul J., Matson, Wayne, Salat, David H., Hersch, Steven M.
Publicado em 2014

Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology

Por Freeman, Thomas B., Cicchetti, Francesca, Hauser, Robert A., Deacon, Terrence W., Li, Xiao-Jiang, Hersch, Steven M., Nauert, G. Michael, Sanberg, Paul R., Kordower, Jeffrey H., Saporta, Samuel, Isacson, Ole
Publicado em 2000

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

Por Hu, Yi, Chopra, Vanita, Chopra, Raman, Locascio, Joseph J., Liao, Zhixiang, Ding, Hongliu, Zheng, Bin, Matson, Wayne R., Ferrante, Robert J., Rosas, H. Diana, Hersch, Steven M., Scherzer, Clemens R.
Publicado em 2011